← back to search

Carolina P. Schröder

KU Leuven · BE
Area of research
Oncology · Radiology, Nuclear Medicine and Imaging
Research interest
Research focused on Breast cancer and Metastatic breast cancer, with related work in Nuclear medicine, Atezolizumab, Oncology. Notable publications include '89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer', 'Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition', and 'Clinical Validity of 16α-[ 18 F]Fluoro-17β-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer'.
h-index
citations
982
works
7
NIH funding
primary concept
email

Recent publications

Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, -Low, and -Positive Metastatic Breast Cancer
Journal of Nuclear Medicine 2024cited by 18position: lastdoi
Clinical Validity of 16α-[<sup>18</sup>F]Fluoro-17β-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer
Journal of Clinical Oncology 2022cited by 67position: lastdoi
First-time imaging of [89Zr]trastuzumab in breast cancer using a long axial field-of-view PET/CT scanner
European Journal of Nuclear Medicine and Molecular Imaging 2022cited by 19position: middledoi
Child development at 6 years after maternal cancer diagnosis and treatment during pregnancy
European Journal of Cancer 2020cited by 61position: middledoi
Assessment of Bone Lesions with<sup>18</sup>F-FDG PET Compared with<sup>99m</sup>Tc Bone Scintigraphy Leads to Clinically Relevant Differences in Metastatic Breast Cancer Management
Journal of Nuclear Medicine 2020cited by 26position: lastdoi
Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition
European Journal of Cancer 2019cited by 68position: lastdoi
89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer
Nature Medicine 2018cited by 723position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Sjoerd G. Elias · University Medical Center Utrecht5 papers (2018–2024)Andor W.J.M. Glaudemans · University Medical Center Groningen4 papers (2019–2022)Adrienne H. Brouwers · Fetal Medicine Foundation Belgium4 papers (2018–2024)Thomas C. Kwee · Utrecht University3 papers (2018–2020) · 3 papers (2018–2024) · 2 papers (2022–2024)Marjolijn N. Lub–de Hooge · University Medical Center Groningen2 papers (2018–2024) · 2 papers (2019–2022)Bert van der Vegt · University of London2 papers (2022–2024)Geke A.P. Hospers · University Medical Center Groningen2 papers (2019–2022) · 2 papers (2022–2024) · 2 papers (2019–2022)Sjoukje F. Oosting · Baxter (United States)2 papers (2018–2020)Ronald Boellaard · Netherlands Institute for Neuroscience2 papers (2018–2022)Elisabeth G.E. de Vries · Amsterdam Neuroscience2 papers (2018–2020)Agnes Jager · Erasmus MC2 papers (2022–2024) · 2 papers (2022–2024)Sandra Sanabria Bohórquez · KU Leuven1 papers (2018–2018)Anne I.J. Arens · Radboud University Nijmegen1 papers (2024–2024) · 1 papers (2020–2020)